Donghua Zhu

US Patent:

20200253968, Aug 13, 2020

Filed:

Oct 16, 2019

Appl. No.:

16/654442

Inventors:

- North Chicago IL, US
Ulrich Westedt - Schriesheim, DE
Ute Lander - Dannenfels, DE
Katrin Schneider - Mannheim, DE
Benedikt Steitz - Kallstadt, DE
Thomas Mueller - Ludwigshafen, DE
Regina Reul - Mannheim, DE
Constanze Obermiller - Heidelberg, DE
Adivaraha Jayasankar - Naperville IL, US
Michael Simon - Landau, DE
Yi Gao - Vernon Hills IL, US
Harald Hach - Oberotterbach, DE
Samuel Kyeremateng - Mannheim, DE
Katharina Asmus - Neustadt a.d.W., DE
Ping Tong - Potomoc MD, US
Donghua Zhu - Vernon Hills IL, US
Marius Naris - Downers Grove IL, US
Colleen Garrett - Chicago IL, US

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

A61K 31/498
A61K 31/454
A61K 9/24
A61K 9/20
A61K 9/14
A61K 31/4985

Abstract:

The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

US Patent:

20190216882, Jul 18, 2019

Filed:

Dec 20, 2018

Appl. No.:

16/227994

Inventors:

- North Chicago IL, US
Ulrich Westedt - Schriesheim, DE
Ute Lander - Dannenfels, DE
Katrin Schneider - Mannheim, DE
Benedikt Steitz - Kallstadt, DE
Thomas Mueller - Ludwigshafen, DE
Regina Reul - Mannheim, DE
Constanze Obermiller - Heidelberg, DE
Adivaraha Jayasankar - Naperville IL, US
Michael Simon - Landau, DE
Yi Gao - Vernon Hills IL, US
Harald Hach - Oberotterbach, DE
Samuel Kyeremateng - Mannheim, DE
Katharina Asmus - Neustadt a.d.W., DE
Ping Tong - Potomoc MD, US
Donghua Zhu - Vernon Hills IL, US
Marius Naris - Downers Grove IL, US
Colleen Garrett - Chicago IL, US

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

A61K 38/06
A61K 31/4184
A61K 31/498
A61K 31/454
A61K 9/24
A61K 9/16
A61K 9/20
A61K 9/14
A61K 9/28

Abstract:

The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

US Patent:

20190202812, Jul 4, 2019

Filed:

Apr 25, 2017

Appl. No.:

16/166753

Inventors:

- North Chicago IL, US
Colleen C. Garrett - Chicago IL, US
Fredrik Lars Nordstrom - Evanston IL, US
Ahmad Y. Sheikh - Deerfield IL, US
Geoff G. Zhang - Vernon Hills IL, US
Donghua Zhu - North Chicago IL, US

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

C07D 403/14

Abstract:

The present invention features crystalline polymorphs of dimethyl (2S,2′S)-1,1,-((2S,2′S)-2,2,-(4,4,-((2S,5S)-1-(4-tert-butylphenyl) pyrrolidine-2,5-diyl) bis (4,1-phenylene)) bis (azanediyl) bis (oxomethylene) bis (pyrrolidine-2,1-diyl)) bis (3-methyl-1-oxobutane-2,1-diyl) dicarbamate i.e. ombitasvir, compound (I), which is a potent HCV NS5A inhibitor. In one embodiment, a crystalline form of Compound (I) has characteristic peaks in the PXRD pattern as shown in one of FIGS. -.

US Patent:

20160375017, Dec 29, 2016

Filed:

Jul 18, 2016

Appl. No.:

15/212997

Inventors:

- North Chicago IL, US
Yi Gao - Vernon Hills IL, US
Colleen Garrett - Chicago IL, US
Harald Hach - Oberotterbach, DE
Adivaraha Jayasankar - Naperville IL, US
Kyeremateng Samuel - Mannheim, DE
Ute Lander - Dannenfels, DE
Thomas Mueller - Wiesbaden, DE
Marius Naris - Downers Grove IL, US
Constanze Obermiller - Heidelberg, DE
Regina Reul - Mannheim, DE
Katrin Schneider - Mannheim, DE
Nancy Sever - Northbrook IL, US
Michael Simon - Landau, DE
Benedikt Steitz - Kallstadt, DE
Ping Tong - Potomoc MD, US
Ulrich Westedt - Schriesheim, DE
Donghua Zhu - Vernon Hills IL, US

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

A61K 31/498
A61K 9/20
A61K 9/24
A61K 31/454
A61K 9/10

Abstract:

The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

US Patent:

20160375087, Dec 29, 2016

Filed:

Jun 24, 2016

Appl. No.:

15/192211

Inventors:

- North Chicago IL, US
Ulrich Westedt - Schriesheim, DE
Ute Lander - Dannenfels, DE
Katrin Schneider - Mannheim, DE
Benedikt Steitz - Kallstadt, DE
Thomas Mueller - Ludwigshafen, DE
Regina Reul - Mannheim, DE
Constanze Obermiller - Heidelberg, DE
Adivaraha Jayasankar - Naperville IL, US
Michael Simon - Landau, DE
Yi Gao - Vernon Hills IL, US
Harald Hach - Oberotterbach, DE
Samuel Kyeremateng - Mannheim, DE
Katharina Asmus - Neustadt a.d.W., DE
Ping Tong - Potomoc MD, US
Donghua Zhu - Vernon Hills IL, US
Marius Naris - Downers Grove IL, US
Colleen Garrett - Chicago IL, US

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

A61K 38/06
A61K 9/28
A61K 9/20
A61K 9/16
A61K 31/4184
A61K 9/24

Abstract:

The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

US Patent:

20150322108, Nov 12, 2015

Filed:

May 9, 2014

Appl. No.:

14/274309

Inventors:

- North Chicago IL, US
Lars Fredrik Nordstroem - Evanston IL, US
Donghua Zhu - Vernon Hills IL, US

International Classification:

C07K 5/062

Abstract:

The present invention features crystalline forms of Compound I.